diffuse cutaneous leishmaniasis

dif·fuse cu·ta·ne·ous leish·man·i·a·sis

leishmaniasis caused by several New and Old World species and strains of Leishmania (L. mexicana amazonensis, L. m. pifanoi, possibly L. m. garnhami and L. m. venezuelensis; in Ethiopia, L. aethiopica, and unidentified leishmanial agents in Namibia and Tanzania). The condition is associated with a suppressed cell-mediated immune response, so that the nonulcerating, nonnecrotizing cutaneous lesions can spread widely over the body; great numbers of parasite-filled macrophages are found in the dermal lesions. Healing does not seem to occur unless an acquired cellular hypersensitivity can develop.
See also: cutaneous leishmaniasis.

dif·fuse cu·ta·ne·ous leish·man·i·a·sis

(di-fyūs' kyū-tā'nē-ŭs lēsh'mă-nī'ă-sis)
A disorder caused by several New and Old World species and strains of Leishmania. The condition is associated with a suppressed cell-mediated immune response.
References in periodicals archive ?
Leishmaniasis also has some serious complications such as post-kala-azar dermal leishmaniasis (PKDL) which is a complication of VL that results in nodular rashes in patients recovered from VL [73, 98] and diffuse cutaneous leishmaniasis (DCL), which is believed to be a result of an immunological defect of the humanhost [99].
Abbreviations CL: Cutaneous leishmaniasis MCL: Mucocutaneous leishmaniasis VL: Visceral leishmaniasis PCR: Polyclonal chain reaction ELISA: Enzyme Linked Immunosorbent Assay IFA: Indirect Fluorescent Antibody DAT: Direct Agglutination Test LST: Leishmanin Skin Test PKDL: Post-kala-azar dermal leishmaniasis DCL: Diffuse cutaneous leishmaniasis IV: Intravenous IM: Intramuscular IL: Intralymphatic GIS: Geographical Information System.
Monocyte suppression of antigen specific responses in diffuse cutaneous leishmaniasis patients Dominican republic.
amazonensis have been isolated from a diffuse cutaneous leishmaniasis case in Bolivia [41].
chagasi in a case of diffuse cutaneous Leishmaniasis in Bolivia," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol.
Several Leishmania species are able to cause a wide spectrum of clinical manifestations of CL, ranging from the mild cutaneous form (localized cutaneous leishmaniasis, LCL) to multiple non ulcerative nodules (diffuse cutaneous leishmaniasis, DCL) and the disfiguring mucosal form (mucocutaneous leishmaniasis, MCL) [2].
Diffuse cutaneous leishmaniasis (DCL) resembles leprosy and is difficult to treat.
Infections in humans may either be non-apparent or may display a clinical spectrum ranging from localized, sometimes self-healing cutaneous lesions, to severe mutilating mucocutaneous lesions, or diffuse cutaneous leishmaniasis (AKILOV et al., 2007).
Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report.
Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects.
After promising results were obtained with miltefosine in a patient with anergic diffuse cutaneous leishmaniasis (ADCL) in Venezuela (2), the patient received 150 mg/day oral miltefosine (Impavido, Zentaris, Germany) for 98 days and the lesional parasite load was quantified with quantitative nucleic acid sequence-based amplification (3).

Full browser ?